Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients.
Biomed Res Int
; 2014: 689426, 2014.
Article
em En
| MEDLINE
| ID: mdl-24511542
ABSTRACT
OBJECTIVE:
This longitudinal study aims to determine if statins inhibit the response to rituximab in rheumatoid arthritis (RA) patients.METHODS:
41 patients initiating rituximab were included; 17 patients were exposed to the combination of statins and rituximab. The total cholesterol, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were assessed. The clinical response was evaluated using Disease Activity Score (DAS28) and European League against Rheumatism (EULAR) response at 6 and 18 months.RESULTS:
A tendency of increasing in DAS28 was observed in statin-exposed group but the correlation was very weak (at 18 months r = 0.013, P = 0.952). The statin-exposed status was negatively and very weakly correlated with EULAR response at 6 months (r = -0.073, P = 0.661) and 18 months (r = -0.197, P = 0.244). There was a negative correlation between statin-exposed status and inflammatory markers values (ESR and CRP); however, the correlation was very weak. The use of statin did not influence the cardiovascular risk measured by modified Systematic Coronary Risk Evaluation (mSCORE).CONCLUSIONS:
Long-term significant inhibitory effects of statins on rituximab treatment in RA have not been proved using clinical response scores or biologic markers.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Antirreumáticos
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Anticorpos Monoclonais Murinos
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article